

Active substances set

Search phrase: irinotecan hydrochloride trihydrate

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Malignant pancreatic cancer

**Irinotecan
hydrochloride
trihydrate**

Treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in adult patients who have progressed following gemcitabine based therapy.



NO REIMBURSEMENT



ESMO